Department of Reproductive Biology, Carlos Gual Castro", Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Sección XVI, Mexico City, 14080, México.
J Endocrinol Invest. 2023 Jul;46(7):1333-1341. doi: 10.1007/s40618-022-01977-2. Epub 2023 Jan 27.
The contraceptive gestodene is a potent synthetic progestin used in several low-dose contraceptive formulations. Clinical studies reported a relationship between long-term use of combined oral contraceptives containing gestodene (GDN) and profound alterations in glucose metabolism in women. The observation that contraceptive synthetic progestins exert hormone-like effects other than their progestational activities, prompted us to investigate whether GDN may induce estrogen-like effects, even though GDN does not interact with estrogen receptors. The aim of this study was to investigate whether GDN affect pancreatic β-cell activity, directly or through its conversion to other bioactive metabolites.
The effects of GDN and its two derivatives 3β,5α-tetrahydro-GDN and 3α,5α-tetrahydro-GDN on insulin 2 (Ins II) and glucokinase (Gk) expression and glucose-stimulated insulin secretion were determined in pancreatic islets from female rats.
Gestodene did exert significant effects on islet β-cells activity. The most striking finding was that 3β,5α-tetrahydro-GDN and 3α,5α-tetrahydro-GDN had greater stimulatory effects on Ins II and Gk expression than that observed with GDN, consistent with their effects on glucose-stimulated insulin secretion. The effects on gene expression induced by GDN-derivatives were abolished by ICI 182,780 and MPP. In addition, the presence of inhibitors of androgen and progestin-metabolizing enzymes eliminated gene expression induced by GDN. These results indicated that GDN is metabolized to A-ring reduced metabolites with estrogen-like activities and through this mechanism, GDN may affect β-cell activity.
Altogether, the data suggest that 19-nortestosterone-derived contraceptives such as GDN, possess insulinotropic effects through their conversion into metabolites with intrinsic estrogen-like activity in pancreatic β-cells.
避孕药左炔诺孕酮是一种强效合成孕激素,被应用于几种低剂量的避孕药中。临床研究报告称,长期使用含有左炔诺孕酮(GDN)的复方口服避孕药与女性糖代谢的深刻变化有关。观察到避孕合成孕激素除了具有孕激素活性外,还具有类激素作用,这促使我们研究左炔诺孕酮是否可能诱导雌激素样作用,尽管左炔诺孕酮不与雌激素受体相互作用。本研究旨在探讨左炔诺孕酮是否通过其转化为其他生物活性代谢物或直接影响胰岛β细胞的活性。
在雌性大鼠胰岛中,测定了左炔诺孕酮及其两种衍生物 3β,5α-四氢左炔诺孕酮和 3α,5α-四氢左炔诺孕酮对胰岛素 2(Ins II)和葡萄糖激酶(Gk)表达以及葡萄糖刺激的胰岛素分泌的影响。
左炔诺孕酮确实对胰岛β细胞的活性有显著影响。最显著的发现是,3β,5α-四氢左炔诺孕酮和 3α,5α-四氢左炔诺孕酮对 Ins II 和 Gk 表达的刺激作用大于左炔诺孕酮,这与它们对葡萄糖刺激的胰岛素分泌的作用一致。GDN 衍生物引起的基因表达的作用被 ICI 182,780 和 MPP 所消除。此外,雄激素和孕激素代谢酶的抑制剂的存在消除了左炔诺孕酮诱导的基因表达。这些结果表明,左炔诺孕酮代谢为具有雌激素样活性的 A 环还原代谢物,通过这种机制,左炔诺孕酮可能影响β细胞的活性。
总之,数据表明,19-去甲睾酮衍生的避孕药如左炔诺孕酮通过转化为具有内在雌激素样活性的代谢物在胰岛β细胞中具有胰岛素增敏作用。